Johnson & Johnson MedTech announced the U.S. launch of its Cereglide 42 and Cereglide 57 aspiration catheters, along with the Innerglide 7 delivery aid, as the latest in its aspiration-first stroke portfolio.

These catheters complete the Cereglide family. They’re designed to help reach and remove distal clots more consistently while simplifying procedural decisions and supporting performance in ischemic stroke cases.

“We designed this multi-axial system to address procedural challenges physicians face when treating stroke,” said Christian Cuzick, Worldwide President, Neurovascular, MedTech, Johnson & Johnson. “With this expanded portfolio, we’re simplifying decisions, enhancing consistency across device sizes, and reinforcing our commitment to helping improve patient outcomes.”

Cereglide 24 and 57 are built with variable-stiffness construction that offers flexible distal navigation and supportive proximal control. Both catheters feature a hydrophilic coating for reduced friction in tortuous anatomy and a radiopaque tip marker for fluoroscopic visibility. They can be tracked to the M2 with J&J’s TruCourse technology.

“Accessing distal occlusions remains one of the biggest technical challenges we face, especially in smaller or more tortuous vessels,” said Ameer E. Hassan, DO, FAHA, FSVIN, Neuroscience Institute, Valley Baptist Medical Center, Harlingen, Texas. “In my experience, CEREGLIDE 42 and 57 track reliably while maintaining strong proximal support, even over multiple passes.3 That balance of flexibility and control gives me greater confidence when performing aspiration-first thrombectomy in more complex anatomy.”

Innerglide 7 supports the advancement of large-bore catheters like Cereglide 71 to distal clot locations. It has a hydrophilic-coated shaft, 1.5 cm soft distal tip, and compatibility with 0.024” guidewires.

“Reaching the M2 segment with large-bore aspiration systems can be technically demanding,” said Dr. Hassan. “INNERGLIDE 7 provides the additional support needed to consistently deliver CEREGLIDE 71 into more distal targets with smoother navigation and less resistance. I am a firm believer in delivery catheter technology like Innerglide.”

Last month, the company announced that it submitted its Ottava robotic surgical system to the U.S. Food and Drug Administration (FDA) in an application for De Novo classification.